ESMO Voices from China | Professor Wei Li: TELEGRAM Study Reveals Differences in Musculoskeletal Pain Outcomes Between Tuppefilgrastim and Other Long-Acting G-CSFs During Breast Cancer Chemotherapy

ESMO Voices from China | Professor Wei Li: TELEGRAM Study Reveals Differences in Musculoskeletal Pain Outcomes Between Tuppefilgrastim and Other Long-Acting G-CSFs During Breast Cancer Chemotherapy

Chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) are important complications that need to be prevented during breast cancer chemotherapy. The use of long-acting granulocyte colony-stimulating factors (G-CSFs) helps prevent these complications and supports the delivery of chemotherapy. At the same time, reducing treatment-related pain has become an important consideration in optimizing supportive care.
2026 IFSC | Professor Daichi Inoue Explores Clonal Evolution in Leukemia with Extremely Poor Prognosis: SETBP1 Abundance-Dependent Mechanisms and Early Intervention Strategies

2026 IFSC | Professor Daichi Inoue Explores Clonal Evolution in Leukemia with Extremely Poor Prognosis: SETBP1 Abundance-Dependent Mechanisms and Early Intervention Strategies

Basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines are currently among the most closely watched frontiers in global hematology and translational medicine. With these topics at its core, the 10th International Forum on Stem Cells (IFSC) was successfully held, bringing together leading experts and scholars from around the world to explore scientific discoveries and technological innovation. The forum showcased the latest advances in basic, clinical, and translational research on hematopoietic stem cells, with the aim of promoting collaborative innovation in the global stem cell field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Daichi Inoue of Osaka University, Japan, to share his latest research findings and perspectives on "Clonal Evolution and Targeted Intervention in Leukemia with Extremely Poor Prognosis." The key insights are presented below.
Published in The Lancet | First-in-Class Bispecific ADC Iza-bren Reshapes Clinical Treatment Decision-Making and Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer

Published in The Lancet | First-in-Class Bispecific ADC Iza-bren Reshapes Clinical Treatment Decision-Making and Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer

The 2026 ESMO Congress brought major advances to the forefront of oncology. Iza-bren (BL-B01D1/伦康依隆妥单抗), the world's first-in-class and first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC), made a striking appearance with data from its pivotal Phase III PANKU-Breast01 study. The study presented its prespecified interim analysis results in full for the first time in a late-breaking abstract (LBA).
2026 East China Breast Cancer Salon | Professor Yongmei Yin: A Decade of Academic Exchange and Mentorship—Advancing Evidence-Based Practice and Standardized Breast Cancer Care

2026 East China Breast Cancer Salon | Professor Yongmei Yin: A Decade of Academic Exchange and Mentorship—Advancing Evidence-Based Practice and Standardized Breast Cancer Care

Against the vibrant autumn backdrop of Nanjing, breast cancer experts gathered on October 11, 2026, for the 2026 East China Breast Cancer Salon. Under the theme “Ninety Years of Compassion and Dedication, Passing the Torch of Medical Excellence,” the meeting focused on advances in breast cancer diagnosis and treatment, clinical implementation, and the development of the specialty. Over the past decade, the salon has established a strong regional foundation while benchmarking its work against international standards, creating an academic platform that integrates cutting-edge research, clinical application, and professional training.
SIBCS Special Feature | Professor Liang Huang: Oncologic Safety Comes First, with Aesthetic Outcomes as an Added Benefit—Individualized Decisions in Breast-Conserving Surgery and Breast Reconstruction

SIBCS Special Feature | Professor Liang Huang: Oncologic Safety Comes First, with Aesthetic Outcomes as an Added Benefit—Individualized Decisions in Breast-Conserving Surgery and Breast Reconstruction

As more patients with breast cancer seek both oncologic cure and preservation of breast appearance, breast-conserving surgery and breast reconstruction have become increasingly important components of comprehensive breast cancer care. The challenge is to improve aesthetic outcomes and quality of life while maintaining oncologic safety, ensuring effective local control, and minimizing long-term risks. This requires individualized, multidisciplinary surgical decision-making. At the 19th National Breast Cancer Conference and the 21st Shanghai International Breast Cancer Symposium (SIBCS), Professor Liang Huang of Fudan University Shanghai Cancer Center spoke with Oncology Frontier about balancing oncologic safety and aesthetic outcomes in breast-conserving surgery and reconstruction, selecting techniques for Chinese women with distinct breast anatomy, weighing implant-based against autologous tissue reconstruction, and the roles of multidisciplinary team (MDT) collaboration and patient communication.
“Zhong” Voice, “Hui” Insights Series, Episode 33: Exploring IL-1β Blockade Combined with Concurrent Chemoradiotherapy and Maintenance Immunotherapy in Unresectable Stage III NSCLC — An Interpretation of the CHORUS Study

“Zhong” Voice, “Hui” Insights Series, Episode 33: Exploring IL-1β Blockade Combined with Concurrent Chemoradiotherapy and Maintenance Immunotherapy in Unresectable Stage III NSCLC — An Interpretation of the CHORUS Study

Advances in modern oncology have introduced a range of groundbreaking treatment approaches for lung cancer, making it one of the fastest-evolving solid tumors. To help clinicians gain a deeper and more comprehensive understanding of major developments in this field, Oncology Frontier has partnered with Professor Hua Zhong, Director of the Department of Pulmonary and Critical Care Medicine at Shanghai Chest Hospital, and Professor Baohui Han to launch a series of clinical updates titled “Zhong” Voice, “Hui” Insights. Through expert interpretations of high-quality clinical studies in lung cancer, the series aims to promote improvements in clinical practice and patient care.
CSCO Global Perspectives | Professor Yi-Long Wu in Conversation with Professor Everett Vokes: Advances in MET-Amplified NSCLC—From Resistance Mechanism to Actionable Oncogenic Driver

CSCO Global Perspectives | Professor Yi-Long Wu in Conversation with Professor Everett Vokes: Advances in MET-Amplified NSCLC—From Resistance Mechanism to Actionable Oncogenic Driver

The 2026 CSCO Academic Annual Meeting was held in Jinan from September 16 to 19, bringing together oncology experts from China and around the world. On this occasion, Oncology Frontier invited Professor Yi-Long Wu of Guangdong Provincial People's Hospital to speak with Professor Everett Vokes, Chair of the Department of Medicine at the University of Chicago and former President of the American Society of Clinical Oncology (ASCO). Their discussion explored the biological characteristics of MET-amplified non-small cell lung cancer (NSCLC), the current diagnostic and treatment landscape in China and the United States, and future directions for international collaboration.
CSCO 2026 | Professor Xinghao Ai: Obrixtamig Plus First-Line Standard Therapy Shows Encouraging Efficacy in Extensive-Stage Small Cell Lung Cancer

CSCO 2026 | Professor Xinghao Ai: Obrixtamig Plus First-Line Standard Therapy Shows Encouraging Efficacy in Extensive-Stage Small Cell Lung Cancer

At the selected target dose of 60 mg, obrixtamig combined with standard therapy as first-line induction and maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) achieved an objective response rate of 76% and a 6-month progression-free survival rate of 85%. The safety profile was consistent with the known safety profiles of the individual agents.
ESMO Preview | Professor Yongmei Yin: A New Breakthrough in HR+/HER2− Advanced Breast Cancer — Iza-bren Ushers in a New Era of Bispecific ADC Therapy

ESMO Preview | Professor Yongmei Yin: A New Breakthrough in HR+/HER2− Advanced Breast Cancer — Iza-bren Ushers in a New Era of Bispecific ADC Therapy

The 2026 Congress of the European Society for Medical Oncology (ESMO) is fast approaching. Yizekang (lunvenlatug vedotin, BL-B01D1/iza-bren), the world's first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC), has achieved the primary endpoint in PANKU-Breast01, a randomized, controlled Phase III clinical trial in patients with HR+/HER2− advanced breast cancer whose disease progressed after endocrine therapy plus a CDK4/6 inhibitor and who had failed one to two lines of chemotherapy. The study has been selected for a Late-Breaking Abstract (LBA), one of the highest-profile presentation categories at the ESMO Congress. Oncology Frontier invited Professor Yongmei Yin of Jiangsu Province Hospital to discuss unmet clinical needs, analyze the potential clinical value of bispecific ADCs, and share her expert insights.